Net cash used in operating activities in the quarter ended March 31, 2023, Was approximately $5,900,000 as compared to $4,800,000 in the Q1 of 2022. This increase is primarily due to our investment in product evolution expenditures. We expect the investment level in R and D To begin tapering off for the remainder of the year, total liabilities decreased from $7,700,000 As of December 31, 2022, to $6,500,000 as of March 31, 2023, Contributing to the $5,900,000 of net cash used in operating activities in the Q1 of 2023. Cash, cash equivalents and restricted cash at March 31, 2023, totaled approximately $12,200,000 as compared to approximately $18,000,000 as of December 31, 2022. Looking ahead, For the full year 2023, we are reiterating our net revenue guidance of $14,000,000 to $15,000,000 representing more than 60% growth over 2022.